| Pan-SHIP1/2 inhibitors promote microglia effector functions essential for CNS homeostasis C Pedicone, S Fernandes, OM Dungan, SM Dormann, DR Viernes, ... Journal of cell science 133 (5), jcs238030, 2020 | 46 | 2020 |
| Targeting SHIP1 and SHIP2 in Cancer C Pedicone, ST Meyer, JD Chisholm, WG Kerr Cancers 13 (4), 890, 2021 | 25 | 2021 |
| Small molecule targeting of SHIP1 and SHIP2 WG Kerr, C Pedicone, S Dormann, A Pacherille, JD Chisholm Biochemical Society Transactions 48 (1), 291-300, 2020 | 20 | 2020 |
| Discovery of a novel SHIP1 agonist that promotes degradation of lipid-laden phagocytic cargo by microglia C Pedicone, S Fernandes, A Matera, ST Meyer, S Loh, JH Ha, D Bernard, ... IScience 25 (4), 2022 | 15 | 2022 |
| Multistep IgE mast cell desensitization is a dose-and time-dependent process partially regulated by SHIP-1 A Adnan, S Acharya, LA Alenazy, L de Las Vecillas, P Giavina Bianchi, ... The Journal of Immunology 210 (6), 709-720, 2023 | 7 | 2023 |
| Obesity control by SHIP inhibition requires pan-paralog inhibition and an intact eosinophil compartment S Fernandes, N Srivastava, C Pedicone, R Sudan, EA Luke, OM Dungan, ... Iscience 26 (2), 2023 | 4 | 2023 |
| LRBA deficiency can lead to lethal colitis that is diminished by SHIP1 agonism R Sudan, S Fernandes, N Srivastava, C Pedicone, ST Meyer, ... Frontiers in Immunology 13, 830961, 2022 | 2 | 2022 |
| SHIP inhibition mediates select TREM2-induced microglial functions GS Ramakrishnan, WL Berry, A Pacherille, WG Kerr, JD Chisholm, ... Molecular Immunology 170, 35-45, 2024 | | 2024 |
| Methods of activating microglial cells W Kerr, C Pedicone, JD Chisolm, S Dormann US Patent App. 17/262,784, 2022 | | 2022 |
| Targeting SHIP paralogs to promote microglial effector function in the CNS C Pedicone | | 2022 |
| Novel anti-Trop-2 monoclonal antibodies with unique binding specificities show therapeutic synergy against most human cancers E Guerra, M Trerotola, V Relli, C Pedicone, AD Amore, F Dini, ... Cancer Research 77 (13_Supplement), 4588-4588, 2017 | | 2017 |
| Novel domain-targeted anti-Trop-2 monoclonal antibodies to elicit therapeutic synergy against multiple human cancers. S Alberti, M Trerotola, V Relli, C Pedicone, A D'Amore, F Dini, ... Journal of Clinical Oncology 35 (15_suppl), e14002-e14002, 2017 | | 2017 |
| Novel anti-Trop-2 monoclonal antibodies with unique binding specifıcities show therapeutic synergy against most human cancers M Trerotola, V Relli, C Pedicone, A D'Amore, F Dini, S Fratarcangeli, ... Proceedings of the American Association for Cancer Research AACR Annual …, 2017 | | 2017 |
